title: Sclerosing encapsulating peritonitis: a case series from a single U.K. center during a 10-year period.
abstract: Sclerosing encapsulating peritonitis (SEP) is a serious complication of peritoneal dialysis (PD). Previous reports place the prevalence of SEP at 0.54%-7.3%. We estimated the prevalence of SEP in our unit to be 1.4% over the period 1989-1999. We here present the 6 identified cases. All of the patients presented with small-bowel obstruction; hemorrhagic ascites was identified in 3 cases. All 6 patients experienced ultrafiltration inadequacy, and 5 were treated with glucose polymer (icodextrin; duration of treatment: 1 month-2.5 years). Peritoneal dialysis was stopped at the time of diagnosis in 2 cases. In the other 4 cases, PD had been withdrawn some time prior to the SEP being diagnosed (2 weeks-5 years). Five of the patients have died; the 6th currently uses hemodialysis.
authors.affiliation: Sheffield Kidney Institute, Northern General Hospital, Herries Road, Sheffield, South Yorkshire S6 6FP, U.K.
authors.forename: S B
authors.initials: SB
authors.lastname: Jenkins
authors.forename: B L
authors.initials: BL
authors.lastname: Leng
authors.forename: J R
authors.initials: JR
authors.lastname: Shortland
authors.forename: P W
authors.initials: PW
authors.lastname: Brown
authors.forename: M E
authors.initials: ME
authors.lastname: Wilkie
mesh_terms: D000328:Adult; D000368:Aged; D015314:Dialysis Solutions; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010531:Peritoneal Dialysis, Continuous Ambulatory / Q000009:adverse effects*; D010538:Peritonitis / Q000175:diagnosis / Q000209:etiology* / Q000473:pathology / Q000628:therapy; D012307:Risk Factors; D012598:Sclerosis
chemical_list: D015314:Dialysis Solutions